Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Diseases

  Free Subscription


Articles published in J Gastroenterol Hepatol

Retrieve available abstracts of 144 articles:
HTML format



Single Articles


    November 2022
  1. KARAGIANNAKIS DS, Voulgaris T, Markakis G, Lakiotaki D, et al
    Spleen stiffness can predict liver decompensation and survival in patients with cirrhosis.
    J Gastroenterol Hepatol. 2022 Nov 8. doi: 10.1111/jgh.16057.
    PubMed     Abstract available


  2. OUYANG R, Li H, Tan W, Wang X, et al
    Portal vein thrombosis compromises the performance of MELD and MELD-Na scores in patients with cirrhosis.
    J Gastroenterol Hepatol. 2022 Nov 7. doi: 10.1111/jgh.16053.
    PubMed     Abstract available


  3. ALMOMANI A, Kumar P, Onwuzo S, Boustany A, et al
    Epidemiology and Prevalence of Lean Non-Alcoholic Fatty Liver Disease and Associated Cirrhosis, HCC and Cardiovascular Outcomes in the United States: A Population-Based Study and Review of Literature.
    J Gastroenterol Hepatol. 2022 Nov 3. doi: 10.1111/jgh.16049.
    PubMed     Abstract available


  4. HAKODA H, Kiritani S, Kokudo T, Yoshimura K, et al
    Probe electrospray ionization mass spectrometry-based rapid diagnosis of liver tumors.
    J Gastroenterol Hepatol. 2022;37:2182-2188.
    PubMed     Abstract available


    October 2022
  5. GORGANI F, Esfahani Z, Ghamari SH, Ghasemi E, et al
    Global, Regional, and National Burden and Quality of Care Index of Liver Cirrhosis by Cause from Global Burden of Disease 1990-2019.
    J Gastroenterol Hepatol. 2022 Oct 26. doi: 10.1111/jgh.16041.
    PubMed     Abstract available


  6. MEENA BL, Taneja S, Tandon P, Sahni N, et al
    Home-based Intensive Nutrition Therapy improves Frailty and Sarcopenia in Patients with Decompensated Cirrhosis: A Randomized Clinical Trial.
    J Gastroenterol Hepatol. 2022 Oct 21. doi: 10.1111/jgh.16035.
    PubMed     Abstract available


  7. LIU Y, Chen M
    Targeting hepatic stellate cells may serve as a promising target for hepatic steatosis.
    J Gastroenterol Hepatol. 2022 Oct 18. doi: 10.1111/jgh.16028.
    PubMed    


  8. SARAIVA RO, Gamelas V, Canha MI, Carvalho D, et al
    Hepatobiliary and Pancreatic: An unusual cause of biliary obstruction.
    J Gastroenterol Hepatol. 2022 Oct 10. doi: 10.1111/jgh.16009.
    PubMed    


  9. HOU G, Xu W, Ding D, Tian T, et al
    Metabolome and Transcriptome Integration Reveals Metabolic Profile of Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2022 Oct 8. doi: 10.1111/jgh.16024.
    PubMed     Abstract available


  10. FERNANDEZ M, Lokan J, Leung C, Grigg A, et al
    A critical evaluation of the role of iron overload in fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:1873-1883.
    PubMed     Abstract available


  11. LIN CL, Tai CM, Huang JF, Liu CJ, et al
    The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
    J Gastroenterol Hepatol. 2022;37:1901-1910.
    PubMed     Abstract available


  12. TONTIKIDOU C, Makri ES, Evripidou K, Goulis DG, et al
    Circulating adiponectin in patients with nonalcoholic fatty liver disease-related liver fibrosis: A systematic review and a meta-analysis.
    J Gastroenterol Hepatol. 2022;37:1853-1864.
    PubMed     Abstract available


    September 2022
  13. ZHANG C, Dai D, Zhang W, Yang W, et al
    Role of m6A RNA methylation in the development of hepatitis B virus-associated hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2022 Sep 6. doi: 10.1111/jgh.15999.
    PubMed     Abstract available


  14. LIM SZ, Chuah KH, Rajaram RB, Stanley K, et al
    Epidemiological trends of gastrointestinal and liver diseases in Malaysia: A single-center observational study.
    J Gastroenterol Hepatol. 2022;37:1732-1740.
    PubMed     Abstract available


  15. JEE JJ, Lim J, Park S, Koh H, et al
    Gut microbial community differentially characterizes patients with nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:1822-1832.
    PubMed     Abstract available


  16. INADA K, Tamaki N, Kurosaki M, Kirino S, et al
    Validation of magnetic resonance elastography plus fibrosis-4 for significant fibrosis in nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:1726-1731.
    PubMed     Abstract available


    August 2022
  17. PRINCE DS, Schlaphoff G, Davison SA, Huo YR, et al
    Selective internal radiation therapy for hepatocellular carcinoma: A 15-year multicenter Australian cohort study.
    J Gastroenterol Hepatol. 2022 Aug 28. doi: 10.1111/jgh.15986.
    PubMed     Abstract available


  18. KAWAHARA A, Kanno K, Yonezawa S, Otani Y, et al
    Depletion of hepatic stellate cells inhibits hepatic steatosis in mice.
    J Gastroenterol Hepatol. 2022 Aug 6. doi: 10.1111/jgh.15974.
    PubMed     Abstract available


  19. POHL K, Moodley P, Dhanda A
    The effect of increasing intestinal short-chain fatty acid concentration on gut permeability and liver injury in the context of liver disease: A systematic review.
    J Gastroenterol Hepatol. 2022;37:1498-1506.
    PubMed     Abstract available


  20. ZHANG H, Wang Y, Chen C, Wang B, et al
    Non-alcoholic fatty liver disease, sleep behaviors, and incident type 2 diabetes.
    J Gastroenterol Hepatol. 2022;37:1633-1640.
    PubMed     Abstract available


  21. HA Y, Chon YE, Kim MN, Lee JH, et al
    Gamma-glutamyl transpeptidase dynamics as a biomarker for advanced fibrosis in non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:1624-1632.
    PubMed     Abstract available


  22. KIM HJ, Park SJ, Park HK, Byun DW, et al
    Association of thyroid autoimmunity with nonalcoholic fatty liver disease in euthyroid middle-aged subjects: A population-based study.
    J Gastroenterol Hepatol. 2022;37:1617-1623.
    PubMed     Abstract available


    July 2022
  23. BINET Q, Annet L, Danse E, Goffette P, et al
    Hepatobiliary and Pancreatic: An uncommon cause of portal hypertension.
    J Gastroenterol Hepatol. 2022 Jul 28. doi: 10.1111/jgh.15961.
    PubMed    


  24. LEE H, Kim BK
    Real-world clinical features, healthcare utilization, and economic burden in decompensated cirrhosis patients; a national database.
    J Gastroenterol Hepatol. 2022 Jul 21. doi: 10.1111/jgh.15962.
    PubMed     Abstract available


  25. FENG G, He N, Xia HH, Mi M, et al
    Machine learning algorithms based on proteomic data mining accurately predicting the recurrence of hepatitis B-related hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2022 Jul 11. doi: 10.1111/jgh.15940.
    PubMed     Abstract available


  26. UFUK F, Aykota MR
    Hepatobiliary and Pancreatic: Todani type I choledochal cyst and cystic malformation of the cystic duct.
    J Gastroenterol Hepatol. 2022 Jul 6. doi: 10.1111/jgh.15931.
    PubMed    


  27. LONARDO A
    Precision medicine in nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:1175-1178.
    PubMed    


  28. GIRI S, Agarwal D, Afzalpurkar S
    GGT dynamic for advanced fibrosis in NAFLD: Novel but not convincing.
    J Gastroenterol Hepatol. 2022;37:1406.
    PubMed    


    June 2022
  29. KAKIZOE M, Nagata K, Sasaki R, Ozawa E, et al
    Hepatobiliary and Pancreatic: Ruptured pseudoaneurysm after endoscopic biliary stenting using the novel double-pit-type plastic stent.
    J Gastroenterol Hepatol. 2022 Jun 27. doi: 10.1111/jgh.15913.
    PubMed    


  30. LIU J, Qian Y, Yang F, Huang S, et al
    Value of prediction-model in distinguishing gallbladder adenoma from cholesterol polyp.
    J Gastroenterol Hepatol. 2022 Jun 24. doi: 10.1111/jgh.15928.
    PubMed     Abstract available


  31. LIU H, Yang XL, Dong ZR, Chen ZQ, et al
    Clinical Benefits of Direct-acting Antivirals Therapy in Hepatitis C Virus Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
    J Gastroenterol Hepatol. 2022 Jun 20. doi: 10.1111/jgh.15915.
    PubMed     Abstract available


  32. WONG YJ, Li J, Liu C, Chen Z, et al
    CHESS-ALARM score to stratify decompensation risk in compensated advanced chronic liver disease patients: An international multicenter study.
    J Gastroenterol Hepatol. 2022;37:1043-1051.
    PubMed     Abstract available


    May 2022
  33. DUNN W, Song X, Koestler D, Grdinovac K, et al
    Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation.
    J Gastroenterol Hepatol. 2022 May 25. doi: 10.1111/jgh.15900.
    PubMed     Abstract available


  34. CHAN SL, Wong N, Lam WKJ, Kuang M, et al
    Personalized treatment for hepatocellular carcinoma: Current status and Future perspectives.
    J Gastroenterol Hepatol. 2022 May 15. doi: 10.1111/jgh.15889.
    PubMed     Abstract available


  35. TENG PC, Agopian VG, Lin TY, You S, et al
    Circulating tumor cells: a step toward precision medicine in hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2022 May 11. doi: 10.1111/jgh.15886.
    PubMed     Abstract available


  36. CHOI AY, Kolb J, Shah S, Chahine A, et al
    Endoscopic ultrasound-guided portal pressure gradient with liver biopsy: 6 years of endo-hepatology in practice.
    J Gastroenterol Hepatol. 2022 May 5. doi: 10.1111/jgh.15875.
    PubMed     Abstract available


  37. WANG X, Gao X, Wu R, Chi X, et al
    Serum qAnti-HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg-positive immune active patients.
    J Gastroenterol Hepatol. 2022 May 4. doi: 10.1111/jgh.15881.
    PubMed     Abstract available


    April 2022
  38. SHINKAI K, Sakamori R, Yamada R, Tahata Y, et al
    Prognostic impact of worsening of esophageal varices after balloon-occluded retrograde transvenous obliteration.
    J Gastroenterol Hepatol. 2022 Apr 17. doi: 10.1111/jgh.15853.
    PubMed     Abstract available


  39. SATO M, Kobayashi T, Soroida Y, Tanaka T, et al
    Development of novel deep multimodal representation learning-based model for the differentiation of liver tumors on B-mode ultrasound images.
    J Gastroenterol Hepatol. 2022;37:678-684.
    PubMed     Abstract available


  40. SASAKI Y, Abe Y, Nishise S, Yagi M, et al
    Low serum pancreatic amylase levels as a novel latent risk factor for colorectal adenoma in non-alcohol drinkers.
    J Gastroenterol Hepatol. 2022;37:660-668.
    PubMed     Abstract available


    March 2022
  41. LEUNG HH, Puspanathan P, Chan AW, Mustapha NRN, et al
    Reliability of the Nonalcoholic Steatohepatitis Clinical Research Network and Steatosis Activity Fibrosis histological scoring systems.
    J Gastroenterol Hepatol. 2022 Mar 31. doi: 10.1111/jgh.15843.
    PubMed     Abstract available


  42. HUANG X, Zhu L, Wang L, Huang W, et al
    YTHDF1 promotes intrahepatic cholangiocarcinoma progression via regulating EGFR mRNA translation.
    J Gastroenterol Hepatol. 2022 Mar 1. doi: 10.1111/jgh.15816.
    PubMed     Abstract available


  43. OGAWA Y, Nakahara T, Ono M, Kawaguchi T, et al
    Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease.
    J Gastroenterol Hepatol. 2022;37:592-599.
    PubMed     Abstract available


  44. HUSSAIN I, Wong YJ, Lohan R, Lin S, et al
    Does preemptive transjugular intrahepatic portosystemic shunt improve survival after acute variceal bleeding? Systematic review, meta-analysis, and trial sequential analysis of randomized trials.
    J Gastroenterol Hepatol. 2022;37:455-463.
    PubMed     Abstract available


  45. YANG W, Yusufu Y, Wang C
    Gastrointestinal: A rare case of upper gastrointestinal bleeding: Splenosis mimicking gastric varices.
    J Gastroenterol Hepatol. 2022 Mar 1. doi: 10.1111/jgh.15795.
    PubMed    


    February 2022
  46. LIU Y, Liu S, Huang J, Zhu Y, et al
    Validation of five hepatic steatosis algorithms in metabolic- associated fatty liver disease: a population based study.
    J Gastroenterol Hepatol. 2022 Feb 16. doi: 10.1111/jgh.15799.
    PubMed     Abstract available


  47. MUNDADA K, Goel A, Paliwal VK, Singh TP, et al
    Short course of low-dose pregabalin is effective for the treatment of restless leg syndrome in patients with cirrhosis: A pilot study.
    J Gastroenterol Hepatol. 2022 Feb 16. doi: 10.1111/jgh.15803.
    PubMed     Abstract available


  48. KEMP W, Clayton-Chubb D, Majeed A, Glenister KM, et al
    Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study.
    J Gastroenterol Hepatol. 2022;37:395-403.
    PubMed     Abstract available


  49. BE KH, Zorron Cheng Tao Pu L, Apostolov R, Vaughan R, et al
    Gastrointestinal: Gastric variceal coil migration: A rare entity in endoscopy.
    J Gastroenterol Hepatol. 2022;37:281.
    PubMed    


    January 2022
  50. YUAN BH, Li RH, Huo RR, Li MJ, et al
    Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.
    J Gastroenterol Hepatol. 2022 Jan 26. doi: 10.1111/jgh.15783.
    PubMed     Abstract available


  51. CHAN WK, Tan SS, Chan SP, Lee YY, et al
    The Malaysian Society of Gastroenterology and Hepatology Consensus Statement on Metabolic Dysfunction-Associated Fatty Liver Disease.
    J Gastroenterol Hepatol. 2022 Jan 25. doi: 10.1111/jgh.15787.
    PubMed     Abstract available


  52. MOLLER S, Henriksen JH, Sjostedt S, Bendtsen F, et al
    Determination of hepatic clearance by derivations of the indocyanine green retention test in cirrhosis.
    J Gastroenterol Hepatol. 2022 Jan 11. doi: 10.1111/jgh.15778.
    PubMed     Abstract available


  53. YU J
    The functional role and translational potential of gut microbiota and microbial metabolites in liver diseases.
    J Gastroenterol Hepatol. 2022;37:5-6.
    PubMed    


  54. LI M, Rajani C, Zheng X, Jia W, et al
    The microbial metabolome in metabolic-associated fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:15-23.
    PubMed     Abstract available


  55. SUK KT, Koh H
    New perspective on fecal microbiota transplantation in liver diseases.
    J Gastroenterol Hepatol. 2022;37:24-33.
    PubMed     Abstract available


  56. PAN Y, Zhang X
    Diet and gut microbiome in fatty liver and its associated liver cancer.
    J Gastroenterol Hepatol. 2022;37:7-14.
    PubMed     Abstract available


    December 2021
  57. AHN HS, Kim HJ, Kang TU, Park SM, et al
    Cholecystectomy reduces the risk of cholangiocarcinoma in patients with complicated gallstones, but has negligible effect on hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2021 Dec 14. doi: 10.1111/jgh.15759.
    PubMed     Abstract available


  58. KERR CJ, Waterworth SP, Brodie D, Sandercock GRH, et al
    The associations between physical activity intensity, cardiorespiratory fitness, and non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:3508-3514.
    PubMed     Abstract available


  59. PAN J, Cen L, Zhou T, Yu M, et al
    Insulin-like growth factor binding protein 1 ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:3438-3447.
    PubMed     Abstract available


  60. HUANG H, Hou J, Liu K, Liu Q, et al
    RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance.
    J Gastroenterol Hepatol. 2021;36:3429-3437.
    PubMed     Abstract available


  61. SATO Y, Yoneda A, Shimizu F, Nishimura M, et al
    Resolution of fibrosis by siRNA HSP47 in vitamin A-coupled liposomes induces regeneration of chronically injured livers.
    J Gastroenterol Hepatol. 2021;36:3418-3428.
    PubMed     Abstract available


  62. ZHU Z, Yin J, Dawsey SM, Liu B, et al
    Association between serum ferritin, incident primary liver cancer, and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: A nested case-control study.
    J Gastroenterol Hepatol. 2021;36:3410-3417.
    PubMed     Abstract available


    November 2021
  63. GAZELAKIS K, Mendis S, Wang S, Wong S, et al
    Hepatobiliary and Pancreatic: Liver lesions in cirrhosis: When to biopsy?
    J Gastroenterol Hepatol. 2021 Nov 22. doi: 10.1111/jgh.15735.
    PubMed    


  64. KIM BH, Yu SJ, Kang W, Cho SB, et al
    Expert Consensus on the Management of Adverse Events in Patients Receiving Lenvatinib for Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2021 Nov 1. doi: 10.1111/jgh.15727.
    PubMed     Abstract available


  65. POTOUPNI V, Georgiadou M, Chatzigriva E, Polychronidou G, et al
    Circulating tumor necrosis factor-alpha levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis.
    J Gastroenterol Hepatol. 2021;36:3002-3014.
    PubMed     Abstract available


  66. LEE S, Kim KW, Lee J, Park T, et al
    Visceral adiposity as a risk factor for lean non-alcoholic fatty liver disease in potential living liver donors.
    J Gastroenterol Hepatol. 2021;36:3212-3218.
    PubMed     Abstract available


  67. KUCHAY MS, Choudhary NS, Gagneja S, Mathew A, et al
    Low skeletal muscle mass is associated with liver fibrosis in individuals with type 2 diabetes and nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:3204-3211.
    PubMed     Abstract available


    October 2021
  68. LE TV, Dinh NBT, Dang MT, Phan NCL, et al
    THE EFFECTS OF AUTOPHAGY INHIBITION BY CHLOROQUINE ON HEPATIC STELLATE CELL ACTIVATION IN CCl4 -INDUCED ACUTE LIVER INJURY MOUSE MODEL.
    J Gastroenterol Hepatol. 2021 Oct 28. doi: 10.1111/jgh.15726.
    PubMed     Abstract available


  69. CHANG WI, Kim BH, Kim YJ, Yoon JH, et al
    The role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib.
    J Gastroenterol Hepatol. 2021 Oct 24. doi: 10.1111/jgh.15722.
    PubMed     Abstract available


  70. NAKATSU G
    Toward a postbiotic era of microbiome science: opportunities to advance immunotherapies for hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2021 Oct 19. doi: 10.1111/jgh.15715.
    PubMed     Abstract available


  71. CHEN T, Zhou K, Sun T, Sang C, et al
    Bile acid glycine:taurine ratios predict the progression of chronic liver disease.
    J Gastroenterol Hepatol. 2021 Oct 16. doi: 10.1111/jgh.15709.
    PubMed     Abstract available


  72. HUO TI, Ho SY, Liao JI
    Improved patient survival in hepatitis C virus-related hepatocellular carcinoma: Do direct-acting antivirals play a role?
    J Gastroenterol Hepatol. 2021 Oct 15. doi: 10.1111/jgh.15707.
    PubMed    


  73. YIM HJ, Kim W, Ahn SH, Jung YK, et al
    Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients.
    J Gastroenterol Hepatol. 2021 Oct 15. doi: 10.1111/jgh.15710.
    PubMed     Abstract available


  74. OGAWA E, Kawano A, Ooho A, Furusyo N, et al
    Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for HCV infection.
    J Gastroenterol Hepatol. 2021 Oct 7. doi: 10.1111/jgh.15703.
    PubMed     Abstract available


  75. TAMAKI N, Kurosaki M, Takahashi Y, Itakura Y, et al
    Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease.
    J Gastroenterol Hepatol. 2021;36:2960-2966.
    PubMed     Abstract available


  76. CHEN TP, Lin WY, Chiang CH, Shen TH, et al
    Metabolically healthy obesity and risk of non-alcoholic fatty liver disease severity independent of visceral fat.
    J Gastroenterol Hepatol. 2021;36:2903-2910.
    PubMed     Abstract available


  77. HU HT, Wang W, Chen LD, Ruan SM, et al
    Artificial intelligence assists identifying malignant versus benign liver lesions using contrast-enhanced ultrasound.
    J Gastroenterol Hepatol. 2021;36:2875-2883.
    PubMed     Abstract available


  78. RODRIGUEZ-ANTONIO I, Lopez-Sanchez GN, Uribe M, Chavez-Tapia NC, et al
    Role of the inflammasome, gasdermin D, and pyroptosis in non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:2720-2727.
    PubMed     Abstract available


  79. WANG Y, Liu Y
    Gut-liver-axis: Barrier function of liver sinusoidal endothelial cell.
    J Gastroenterol Hepatol. 2021;36:2706-2714.
    PubMed     Abstract available


    September 2021
  80. LI R, Ong Q, Wong CC, Chu ES, et al
    O-GlcNAcylation inhibits hepatic stellate cell activation.
    J Gastroenterol Hepatol. 2021 Sep 21. doi: 10.1111/jgh.15690.
    PubMed     Abstract available


  81. LOCKART I, Hajarizadeh B, Buckley N, Davison S, et al
    All cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy.
    J Gastroenterol Hepatol. 2021 Sep 14. doi: 10.1111/jgh.15687.
    PubMed     Abstract available


  82. YADA S, Sasaki S, Tokuno K, Yamashita Y, et al
    Hepatobiliary and Pancreatic: Extramammary Paget disease of the esophagus.
    J Gastroenterol Hepatol. 2021 Sep 2. doi: 10.1111/jgh.15665.
    PubMed    


  83. PENNISI G, Di Marco V, Buscemi C, Mazzola G, et al
    Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population.
    J Gastroenterol Hepatol. 2021;36:2389-2396.
    PubMed     Abstract available


  84. CHEN D, Zeng R, Teng G, Cai C, et al
    Menstrual blood-derived mesenchymal stem cells attenuate inflammation and improve the mortality of acute liver failure combining with A2AR agonist in mice.
    J Gastroenterol Hepatol. 2021;36:2619-2627.
    PubMed     Abstract available


    August 2021
  85. ZHAO D, Xia L, Geng W, Xu D, et al
    Metformin suppresses IL-22 induced hepatocellular carcinoma by upregulating Hippo signaling pathway.
    J Gastroenterol Hepatol. 2021 Aug 25. doi: 10.1111/jgh.15674.
    PubMed     Abstract available


  86. EMORI T, Nuta J, Kawaji Y, Tamura T, et al
    Value of contrast-enhanced harmonic endoscopic ultrasound for diagnosing hepatic metastases of pancreatic cancer: a prospective study.
    J Gastroenterol Hepatol. 2021 Aug 16. doi: 10.1111/jgh.15661.
    PubMed     Abstract available


  87. OGAWA E, Nakamuta M, Furusyo N, Kajiwara E, et al
    Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by DAAs.
    J Gastroenterol Hepatol. 2021 Aug 9. doi: 10.1111/jgh.15659.
    PubMed     Abstract available


  88. UENO M, Mano T, Kayahara T, Mizuno M, et al
    Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding: It's time to step forward.
    J Gastroenterol Hepatol. 2021 Aug 8. doi: 10.1111/jgh.15652.
    PubMed    


  89. CHEN M, Hu G, Zhou X, Peng Z, et al
    Hsa_circ_0016788 regulates glycolysis and proliferation via miR-506-3p/PARP14 axis of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2021 Aug 2. doi: 10.1111/jgh.15635.
    PubMed     Abstract available


  90. TAHER MK, Crispo JAG, Fortin Y, Moog R, et al
    Systemic quinolones and risk of acute liver failure III: A nested case-control study using a US electronic health records database.
    J Gastroenterol Hepatol. 2021;36:2307-2314.
    PubMed     Abstract available


  91. CHEN H, Johnston A, Palmer A, Mickenbecker M, et al
    Too little, too late: Palliation and end-stage liver disease.
    J Gastroenterol Hepatol. 2021;36:2303-2306.
    PubMed     Abstract available


    July 2021
  92. MAK J, Chan SM, Siu B, Lai J, et al
    Hepatobiliary and Pancreatic: A tree in the liver.
    J Gastroenterol Hepatol. 2021 Jul 27. doi: 10.1111/jgh.15623.
    PubMed    


  93. ATTEBERRY P, Biederman B, Jesudian A, Lucero C, et al
    Mortality, Sepsis, and Organ Failure in Hospitalized Patients with Cirrhosis Vary by Type of Infection.
    J Gastroenterol Hepatol. 2021 Jul 22. doi: 10.1111/jgh.15633.
    PubMed     Abstract available


  94. SHI M, Sheng L, Lian M, Miao Q, et al
    Efficacy and safety of rifampicin in patients with persistent hepatocellular secretory failure.
    J Gastroenterol Hepatol. 2021 Jul 19. doi: 10.1111/jgh.15629.
    PubMed     Abstract available


  95. WU L, Huang XQ, Li N, Xie C, et al
    An MRI Modality for Non-invasively Distinguishing Progression of Liver Fibrosis by Visualizing Hepatic Platelet-Derived Growth Factor Receptor-Beta Expression in Mice.
    J Gastroenterol Hepatol. 2021 Jul 19. doi: 10.1111/jgh.15628.
    PubMed     Abstract available


  96. KRIGE J, Jonas E, Spence R, Bernon M, et al
    Letter to the editor: The complexities of predicting outcome in cirrhotic patients with acute variceal bleeding.
    J Gastroenterol Hepatol. 2021 Jul 12. doi: 10.1111/jgh.15622.
    PubMed    


  97. ITO T, Hanafusa N, Soneda N, Isoai A, et al
    Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) against cirrhotic ascites in comparison with malignancy-related ascites.
    J Gastroenterol Hepatol. 2021 Jul 11. doi: 10.1111/jgh.15620.
    PubMed     Abstract available


  98. LIU CH, Ampuero J, Pavlides M, Wong VW, et al
    Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1754-1768.
    PubMed     Abstract available


  99. KANG HT, Jang K, Jun DW, Yoon EL, et al
    Macro-encapsulation of mesenchymal stem cells in acute and chronic liver injury animal models.
    J Gastroenterol Hepatol. 2021;36:1997-2007.
    PubMed     Abstract available


  100. KULKARNI AV, Anand L, Vyas AK, Premkumar M, et al
    Omega-3 fatty acid lipid emulsions are safe and effective in reducing endotoxemia and sepsis in acute-on-chronic liver failure: An open-label randomized controlled trial.
    J Gastroenterol Hepatol. 2021;36:1953-1961.
    PubMed     Abstract available


  101. NISHIKAWA M, Kinoshita M, Morimoto Y, Ishikiriyama T, et al
    Lipopolysaccharide preconditioning reduces liver metastasis of Colon26 cells by enhancing antitumor activity of natural killer cells and natural killer T cells in murine liver.
    J Gastroenterol Hepatol. 2021;36:1889-1898.
    PubMed     Abstract available


  102. YAMAMOTO K, Ikeya T, Okuyama S, Fukuda K, et al
    The association between non-alcoholic fatty liver disease (with or without metabolic syndrome) and extrahepatic cancer development.
    J Gastroenterol Hepatol. 2021;36:1971-1978.
    PubMed     Abstract available


    June 2021
  103. COUPER MR, Chennapragada M, Magoffin A
    Hepatobiliary and Pancreatic: A rare peribiliary lesion.
    J Gastroenterol Hepatol. 2021 Jun 29. doi: 10.1111/jgh.15556.
    PubMed    


  104. ZULLO A, Soncini M, Bucci C, Marmo R, et al
    Clinical outcomes in cirrhotics with variceal or nonvariceal gastrointestinal bleeding: a prospective, multicenter cohort study.
    J Gastroenterol Hepatol. 2021 Jun 29. doi: 10.1111/jgh.15601.
    PubMed     Abstract available


  105. HO SY, Liu PH, Hsu CY, Ko CC, et al
    Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    J Gastroenterol Hepatol. 2021 Jun 22. doi: 10.1111/jgh.15593.
    PubMed     Abstract available


  106. PHRUEKSOTSAI S, Pinyopornpanish K, Euathrongchit J, Leerapun A, et al
    Dapagliflozin reduces hepatic and visceral fat in type-2 diabetes patients with non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021 Jun 15. doi: 10.1111/jgh.15580.
    PubMed     Abstract available


  107. FAJARDO J, Nunez E, Szafranska J, Poca M, et al
    We report a patient who presented intrahepatic cholangitis and cholecystitis after SARS-CoV-2 infection.
    J Gastroenterol Hepatol. 2021 Jun 9. doi: 10.1111/jgh.15537.
    PubMed    


  108. CHUN HS, Lee JS, Lee HW, Kim BK, et al
    Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes.
    J Gastroenterol Hepatol. 2021;36:1703-1713.
    PubMed     Abstract available


  109. HASSANI ZADEH S, Mansoori A, Hosseinzadeh M
    Relationship between dietary patterns and non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1470-1478.
    PubMed     Abstract available


  110. AHADI M, Molooghi K, Masoudifar N, Namdar AB, et al
    A review of non-alcoholic fatty liver disease in non-obese and lean individuals.
    J Gastroenterol Hepatol. 2021;36:1497-1507.
    PubMed     Abstract available


  111. RHODES FA, Trembling P, Panovska-Griffiths J, Tanwar S, et al
    Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
    J Gastroenterol Hepatol. 2021;36:1435-1449.
    PubMed     Abstract available


  112. LV T, Chen S, Li M, Zhang D, et al
    Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1423-1434.
    PubMed     Abstract available


  113. LIU D, Shen Y, Zhang R, Xun J, et al
    Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
    J Gastroenterol Hepatol. 2021;36:1670-1678.
    PubMed     Abstract available


  114. HUANG Y, Huang F, Yang L, Hu W, et al
    Development and validation of a radiomics signature as a non-invasive complementary predictor of gastroesophageal varices and high-risk varices in compensated advanced chronic liver disease: A multicenter study.
    J Gastroenterol Hepatol. 2021;36:1562-1570.
    PubMed     Abstract available


  115. YIP TC, Wong VW, Wong GL
    Liver-heart connection in diabetes mellitus.
    J Gastroenterol Hepatol. 2021;36:1385-1386.
    PubMed    


    May 2021
  116. ZHOU J, Wang C, Chen Z
    Hepatobiliary and Pancreatic: Castleman disease of the pancreas diagnosed by endoscopic ultrasound.
    J Gastroenterol Hepatol. 2021 May 31. doi: 10.1111/jgh.15520.
    PubMed    


  117. KANEKO S, Kurosaki M, Inada K, Kirino S, et al
    Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients.
    J Gastroenterol Hepatol. 2021 May 31. doi: 10.1111/jgh.15563.
    PubMed     Abstract available


  118. AGARWAL S, Sharma S, Kumar M, Venishetty S, et al
    Development of a machine learning model to predict bleed in esophageal varices in compensated advanced chronic liver disease: A proof of concept.
    J Gastroenterol Hepatol. 2021 May 28. doi: 10.1111/jgh.15560.
    PubMed     Abstract available


  119. MA HL, Chen SD, Zheng KI, Yu Y, et al
    The TA allele of rs2070673 in the CYP2E1 gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021 May 24. doi: 10.1111/jgh.15554.
    PubMed     Abstract available


  120. TAK KY, Jang B, Lee SK, Nam HC, et al
    The prognostic role of M2BPGi compared with the HAP score in hepatocellular carcinoma patients receiving transarterial treatment.
    J Gastroenterol Hepatol. 2021 May 24. doi: 10.1111/jgh.15553.
    PubMed     Abstract available


  121. ZHAO JA, Nie W, Dong L, Liu W, et al
    A curcumin analogue GL63 inhibits the malignant behaviors of hepatocellular carcinoma by inactivating the JAK2/STAT3 signaling pathway via the circZNF83/miR-324-5p/CDK16 axis.
    J Gastroenterol Hepatol. 2021 May 12. doi: 10.1111/jgh.15545.
    PubMed     Abstract available


  122. CHANG H, Li J, Luo Y, Wu B, et al
    TFB2M activates aerobic glycolysis in hepatocellular carcinoma cells through the NAD(+) /SIRT3/HIF-1alpha signaling.
    J Gastroenterol Hepatol. 2021 May 12. doi: 10.1111/jgh.15548.
    PubMed     Abstract available


  123. YANG C, Liu J, Shi Q, Huang S, et al
    Effect of splenectomy on the outcomes in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    J Gastroenterol Hepatol. 2021 May 11. doi: 10.1111/jgh.15543.
    PubMed     Abstract available


  124. XIE JM, Liu JH, Sun YH, Li W, et al
    Hepatobiliary and Pancreatic: Endoscopic resection of biliary ductal tumour.
    J Gastroenterol Hepatol. 2021 May 9. doi: 10.1111/jgh.15518.
    PubMed    


  125. HSU WF, Tsai PC, Chen CY, Tseng KC, et al
    Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (T-COACH).
    J Gastroenterol Hepatol. 2021 May 7. doi: 10.1111/jgh.15538.
    PubMed     Abstract available


  126. CHEN Z, Jiang H, Wang Y, Liang R, et al
    Three-day Postoperative Antibiotics Reduces Post-hepatectomy Infection Rate in HBV-related Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2021 May 4. doi: 10.1111/jgh.15528.
    PubMed     Abstract available


  127. ANAND A, Elhence A, Vaishnav M, Singh AA, et al
    FibroScan-aspartate aminotransferase score in an Asian cohort of non-alcoholic fatty liver disease and its utility in predicting histological resolution with bariatric surgery.
    J Gastroenterol Hepatol. 2021;36:1309-1316.
    PubMed     Abstract available


  128. LI X, Qin P, Cao L, Lou Y, et al
    Dose-response association of the ZJU index and fatty liver disease risk: A large cohort in China.
    J Gastroenterol Hepatol. 2021;36:1326-1333.
    PubMed     Abstract available


  129. TANDON R, Froghi S
    Artificial liver support systems.
    J Gastroenterol Hepatol. 2021;36:1164-1179.
    PubMed     Abstract available


    April 2021
  130. PUDIPEDDI A, Han J, Leong R
    Hepatobiliary and Pancreatic: Right upper quadrant pain and positive Murphy's sign.
    J Gastroenterol Hepatol. 2021 Apr 29. doi: 10.1111/jgh.15510.
    PubMed    


  131. KAPURIA D, Bollipo S, Rabiee A, Ben-Yakov G, et al
    Roadmap to resuming care for liver diseases after coronavirus disease-2019.
    J Gastroenterol Hepatol. 2021;36:885-892.
    PubMed     Abstract available


  132. CHRYSAVGIS L, Papatheodoridi AM, Chatzigeorgiou A, Cholongitas E, et al
    The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:893-909.
    PubMed     Abstract available


  133. SHIGEFUKU R, Iwasa M, Eguchi A, Tamai Y, et al
    Serum copeptin level is a biomarker associated with ascites retention and the formation of a portosystemic shunt in chronic liver disease.
    J Gastroenterol Hepatol. 2021;36:1006-1014.
    PubMed     Abstract available


    March 2021
  134. SUNG YS, Park B, Park HJ, Lee SS, et al
    Radiomics and deep learning in liver diseases.
    J Gastroenterol Hepatol. 2021;36:561-568.
    PubMed     Abstract available


  135. WONG GL, Yuen PC, Ma AJ, Chan AW, et al
    Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis.
    J Gastroenterol Hepatol. 2021;36:543-550.
    PubMed     Abstract available


  136. LEE HW, Sung JJY, Ahn SH
    Artificial intelligence in liver disease.
    J Gastroenterol Hepatol. 2021;36:539-542.
    PubMed     Abstract available


    February 2021
  137. VADARLIS A, Antza C, Bakaloudi DR, Doundoulakis I, et al
    Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:311-319.
    PubMed     Abstract available


    January 2021
  138. YOSHINO K, Taura K, Iwaisako K, Masano Y, et al
    A novel mouse model for cholestasis-induced liver fibrosis resolution by cholecystojejunostomy.
    J Gastroenterol Hepatol. 2021 Jan 15. doi: 10.1111/jgh.15406.
    PubMed     Abstract available


  139. LUM JHM, Cheah MCC, Leow WQ, Wan WK, et al
    Clinical profile of non-alcoholic fatty liver disease in nonobese patients.
    J Gastroenterol Hepatol. 2021;36:257-261.
    PubMed     Abstract available


  140. GRONBAEK H, Moller HJ, Saliba F, Zeuzem S, et al
    Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensation.
    J Gastroenterol Hepatol. 2021;36:240-248.
    PubMed     Abstract available


    October 2020
  141. YANG J, Sontag D, Gong Y, Minuk GY, et al
    Enhanced Gemcitabine Cytotoxicity with Knockdown of Multidrug Resistance Protein Genes in Human Cholangiocarcinoma Cell Lines.
    J Gastroenterol Hepatol. 2020 Oct 1. doi: 10.1111/jgh.15289.
    PubMed     Abstract available


    September 2020
  142. PYO JH, Kim TJ, Lee H, Choi SC, et al
    Proton Pump Inhibitors Use and the Risk of Fatty Liver Disease; A Nationwide Cohort Study.
    J Gastroenterol Hepatol. 2020 Sep 4. doi: 10.1111/jgh.15236.
    PubMed     Abstract available


    August 2020
  143. EFE C, Torgutalp M, Henriksson I, Alalkim F, et al
    Extrahepatic autoimmune diseases in primary biliary cholangitis: prevalence, significance for clinical presentation and disease outcome.
    J Gastroenterol Hepatol. 2020 Aug 13. doi: 10.1111/jgh.15214.
    PubMed     Abstract available


    July 2020
  144. KIM KS, Kwon HM, Jung KW, Sang BH, et al
    Markedly prolonged QTc interval in end-stage liver disease and risk of 30-day cardiovascular event after liver transplant.
    J Gastroenterol Hepatol. 2020 Jul 13. doi: 10.1111/jgh.15179.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: